



THE JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

X

HEALTH SCIENCES LIBRARY

University of Wisconsin
1305 Linden Dr., Madison, Wis. 53706

MAR 25 1986

VOLUME 14 No 1 1986

International Editorial Board

Harry L Arnold Jr, DM (USA)
Professor C N Barnard, MD, MMed, MS, PhD, FACS,
FACC, DSc (Hon Causa), (South Africa)
Professor Aldo Bertelli, MD (Italy)
Professor J Bobon, MD (Belgium)
Joe L Bussey, MD (USA)
C I Chappel, DVM PhD (Canada)
R N Chaudhuri, MD (India)
Professor agr Mohamed Chelli (Tunisia)
Jonathan O Cole, MD (USA)
L K A Derban (Ghana)
J C Devoghel, MD (Belgium)
F Vega Diaz, MD (Spain)
Professor W R Fair, MD, FACS (USA)
Elisabeth Fell, BSc (UK)
John F Fielding, BSc, MD, MRCP (Ireland)
J S Fleming, MD, FRCP (UK)
Celso-Ramon Garcia, MD (USA)
Professor Dr H H van Gelderen (Holland)
Professor Viorel Gligore, MD, DSc (Romania)
Professor Jean Hamburger (France)
A Henderson, MD, FRCP, FRCPath, FRCPA
(Australia)
Professor Vladimir Hudolin (Yugoslavia)
Professor I Iconomov, MD (Bulgaria)
Professor Dr S Jablonska, MD (Poland)
U Jovanovic, MD (Germany)
V V Kalbian, MD, FRCP(E), (Cyprus)
Professor Dr Antal Kaldor, MD (Hungary)
F Kamunvi, MB, ChB, DPH (Kenya)
Professor S Oguz Kayaalp, MD, MS (Turkey)
Professor N N Kipshidze, MD (USSR)
Professor J Knoll, MD (Hungary)
Professor P Lechat (France)
Professor Mario Correa Lima, MD (Brazil)

R E Lister, PhD, BSc, FIBiol (UK)
Professor Dr G Litarczek (Romania)
F Loza, MD (UAR)
Professor T Lynch, FRCPI, FRC Psych, DPM
(Ireland)
Professor William MacGowan, FRCSE, FACS
(Ireland)
Professor Clovis Martins, MD (Brazil)
V C Medvei, MD, FRCP (UK)
M H Melmed, BSc, MB, ChB (Cape Town), MRCOG
(Israel)
Professor J Caria Menders (Portugal)
Professor M Mya-Tu, MD (Burma)
Professor Joseph Naffah (The Lebanon)
Professor Jacob B Natvig, MD (Norway)
W S Ogden, MA, MB, BChir, MRCS Eng, LRCP (UK)
Professor E O Olurin, FRCSE, FRCS, FMCS (Nigeria)
Professor J P Payne, MB, ChB Ed, FFA, RCS Eng (UK)
Professor Pentti Peltola, MD (Finland)
Professor Carlo Perris, MD (Sweden)
Professor Walter Pöedinger, MD (Austria)
Professor Peter Rasmussen (Denmark)
Professor Attilio Reale, MD (Italy)
Professor W Linford Rees, MD, FRCP, DPM (UK)
Professor Karl Rickels, MD (USA)
Professor W J Rudowski, MD (Poland)
Professor Andrew Semple, CBE, VRD, MD, ChB, DPH (UK)
Tan Seng-Huat, MB BS, FFRACS, FFRACCS, AM
(Singapore)
H N Shivapuri, MD (India)
Professor Eugen Spanar (CSSR)
Professor P S J Spencer, BPharm, PhD, FIBiol, MPS (UK)
Professor Salme Vannas, MD (Finland)
Professor A Vannotti, MD (Switzerland)
Tomoji Yanagita, MD (Japan)

The **Journal of International Medical Research** is published six times yearly by Cambridge Medical Publications Ltd. The annual subscription is \$60.00 (£25.00 sterling) post free and the price of single issues \$15.00 (£6.00 sterling) postage extra. Orders for back issues and all correspondence should be sent to The Secretary, Cambridge Medical Publications Ltd, 435/437 Wellingborough Road, Northampton NN1 4EZ, England.

Claims from Subscribers for issues not received should be made within 3 months of publication of the issue concerned. Later claims cannot be honoured free of charge.

All editorial correspondence should be addressed to Dr J Eric Murphy, Editor-in Chief, The Journal of International Medical Research, Editorial Office, 435/437 Wellingborough Road, Northampton NN1 4EZ, England.

All enquiries should be addressed to The Secretary, Cambridge Medical Publications Ltd, at the above address.

The **Journal of International Medical Research** publishes original papers on subjects of current clinical importance and provides an important platform for the publication of the findings of medical research. The Journal accepts contributions on animal pharmacology, clinical pharmacology, pharmacokinetics and drug metabolism, toxicology, teratology and clinical trials. The Journal of International Medical Research from time to time publishes a 'Drug Profile' which offers an opportunity of an abbreviated version of the sort of information required for the registration of a drug and provides an invaluable source of reference and reprints. The Journal also publishes shorter articles on new indications and new formulations of established products. The Journal of International Medical Research is published by Cambridge Medical Publications Limited on a page sponsorship basis, current rates being available on application. Views and factual

claims expressed in individual contributions are personal to the respective contributors and are not necessarily endorsed by the Editors, Advisers, Publishers or Distributors of The Journal of International Medical Research. Readers correspondence will be referred to the appropriate author for reply.

A 'Notice to Contributors' is published on the inside back cover of this issue. The Editor reserves the right to make changes which may clarify or condense papers where this is considered desirable.

The Journal of International Medical Research is distributed throughout the world to Universities, Medical Schools, Medical Libraries, Research Institutions and selected Hospitals in addition to Subscribers both individual, industrial and organizational.

Papers accepted for publication become the absolute copyright of the publishers. The contents of The Journal of International Medical Research are copyright to Cambridge Medical Publications Limited and, subject to the provisions of Section 7 of the Copyright Act, 1956, they may not be reproduced, in whole or in part, stored in a retrieval system or transmitted or distributed in any form or by any means (electronic, mechanical, photocopy, recording or otherwise). Requests for permission to reproduce material elsewhere, either in whole or in part, should be addressed to The Editor, The Journal of International Medical Research, 435/437 Wellingborough Road, Northampton, NN1 4EZ, England.

The appearance of the fee code in the publication (see below) indicates the copyright owners consent that copies of articles may be made for personal or internal use, or for the use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee (\$2.00) through the Copyright Clearance Center (CCC) Transactional Reporting Service, 21 Congress St., Salem, Massachusetts 01970, U.S.A.

© Copyright Cambridge Medical Publications Limited, 1986 0300-0605/86 \$2.00

Treatment of Seasonal Allergic Rhinitis with Flunisolide and Terfenadine

C I Backhouse, MB, BChir, DObst, RCOG, V P Finnamore, BM, BCh, DRCOG and C W Gosden, MB, BS, *The Surgery, Kingston Avenue, East Horsley, Surrey, KT24 6QT, England*

A study of ninety-nine hay fever sufferers was conducted to compare the effect of treatment with flunisolide nasal spray plus terfenadine tablets with that of terfenadine alone. The study was carried out over an 11-week period, which covered the pollen season between May and August. All patients received 60 mg terfenadine twice daily and one group, of forty-nine patients, also received 50 mcg flunisolide to each nostril twice daily.

Clinical assessments of nasal and ocular symptoms were made at admission and following 3, 7 and 11 weeks' treatment. An over-all evaluation of treatment effect was performed at each follow-up visit and nasal examination was carried out. Patients also completed diary cards daily.

Both treatments were effective in reducing symptom severity, in comparison with previous seasons, but the combination treatment gave consistently better symptom relief. Statistically significant differences were detected in favour of the combined treatments group for nasal symptoms. Eye symptoms were found to be relieved to a comparable degree by both treatments. Results from daily patient self-assessments were consistent with these findings.

The over-all evaluations by both patients and doctors were significantly in favour of flunisolide plus terfenadine.

In conclusion, treatment of hay fever with flunisolide in addition to terfenadine was significantly more effective than treatment with the antihistamine alone.

Introduction

Antihistamine compounds and mast cell inhibitors, such as sodium cromoglycate, are long-established treatments for seasonal allergic rhinitis. Topical steroid preparations have since been introduced and flunisolide is one such compound, being a potent corticosteroid. Its efficacy in the treatment of hay fever in general practice has been shown (Backhouse 1979). Superior efficacy to sodium cromoglycate has been demonstrated (Brown,

Engler & English 1981) as has comparable efficacy with beclomethasone dipropionate (Langrick 1984).

Very few direct comparisons have been made between topical corticosteroids and antihistamines, and indeed these two forms of treatment are often prescribed together, possibly because of their different modes of action.

There is little information available on the combined use of topical and systemic

treatments in the control of hay fever symptoms and so it was of interest to compare the effect of terfenadine alone with that of flunisolide and terfenadine. Terfenadine has been chosen because of its reported lack of sedative effect (Backhouse *et al* 1982), this being the major drawback to antihistamine therapy.

The aim of the study was to compare the efficacy of flunisolide plus terfenadine with that of terfenadine alone in relieving symptoms of hay fever. The incidences of side-effects in the two treatment groups were also compared.

Patients and Methods

The study was of single-blind, parallel design with ninety-nine patients being randomly allocated to receive either terfenadine alone (T) or terfenadine plus flunisolide (T + F). The dosages were 60 mg terfenadine twice daily and two 25 mcg sprays flunisolide to each nostril twice daily. Treatment was started before the onset of the pollen season and continued for 11 weeks.

Patients gave verbal informed consent to enter the study and ethical approval was obtained. The study conformed with the Declaration of Helsinki.

Patients were aged thirteen to sixty-five years and had at least a 2-year history of moderate to severe seasonal allergic rhinitis. Patients were excluded from the study if they were pregnant or lactating, if they had a respiratory tract infection or nasal abnormalities causing obstruction. Also excluded were those who had received systemic steroid therapy within the previous 3 months or any anti-allergic treatment within the previous 2 weeks.

Patient history was taken at admission and the usual severity of hay fever symptoms, in previous years, was established. At subsequent assessments, after 3, 7 and 11 weeks, the severity of individual symptoms was recorded and an examination of the nasal mucosa was made. Sneezing and nose blowing were rated as never/seldom (=1), infrequent (=2), frequent (=3) or very frequent (=4). Runny nose, stuffy nose and ocular symptoms were rated as none (=1), mild (=2), moderate (=3) or severe (=4). At each visit an over-all assessment was made, rating the effect of

treatment as excellent, good, poor, none or symptoms worse.

In addition to the assessment visits, patients completed a daily record of the severity of sneezing, runny nose, blocked nose and eye symptoms.

Non-parametric statistical tests were used to analyze the data. Within-group comparisons were made of assessment data with both admission and usual severity scores. Between-group differences were examined for each assessment as well as the changes from admission and from usual severity. Symptom scores from diary card data were also compared.

Results

Forty-nine patients were allocated to the T + F group and fifty to the T group and the groups were well balanced in terms of age, sex, diagnosis and disease history (see Table 1). Patients had, in previous seasons, been treated with a variety of topical and systemic anti-allergic treatments.

Seventy-five patients remained in the study for the full 11 weeks. Seventeen patients withdrew from the T group; reasons for this were poor symptom control (10), headaches (1), pregnancy (1), glandular fever (1), lack of symptoms (2), personal reasons (1), lost to follow-up (1). Five patients from the T + F group withdrew because of poor symptom control (2), personal reasons (2) and leaving the country (1). There was a significant difference between the groups with respect to the total numbers of patients withdrawing ($p < 0.005$) and this was largely accounted for by the patients who withdrew because of inadequate symptom control. Twenty per cent of patients withdrew, for this reason, from the terfenadine group and 4% from the T + F group ($p = 0.015$).

Local pollen counts, recorded for a 6-week period during June and July, indicated that substantial amounts of pollen were released during this time. This period coincided with weeks 3 to 9 of the study. Pollen counts are shown in Figures 1-4.

Table 2 shows the mean symptom scores at each assessment and the significances of the differences between the treatment groups, both on direct comparison and when change from admission and usual severity are considered.

Table 1

Admission characteristics

	Treatment Group	
	T	T + F
n	50	49
Males	23	28
Females	27	21
Mean age \pm s.d. (years)	35.0 \pm 11.0	35.0 \pm 14.3
Mean duration of disease \pm s.d. (years)	17.0 \pm 9.7	18.5 \pm 11.9
Seasonal rhinitis	41	40
Seasonal/perennial rhinitis	9	9
Skin test – positive	15	18
– not known	35	31
Asthma	10	11
Dermatitis	5	8
No other known allergy	35	31
Usual symptom severity Mean score \pm s.d.		
– sneezing	3.1 \pm 0.7	3.1 \pm 0.7
– nose blowing	3.2 \pm 0.6	3.2 \pm 0.6
– runny nose	2.9 \pm 0.8	3.1 \pm 0.6
– stuffy nose	2.6 \pm 0.9	2.9 \pm 1.0
– eye symptoms	3.2 \pm 0.7	3.4 \pm 0.7

All symptoms were at their most severe at week 7, when the pollen level was high. Symptoms were less severe on all occasions in patients in the T + F group and these differences were statistically significant for all nasal symptoms, except for runny nose and stuffy nose at week 11. Differences between the groups with respect to changes from usual severity were significant in most instances, indicating that the combined treatment was more effective than terfenadine alone in reducing the degree of allergic reaction normally experienced.

The over-all response to treatment, as assessed by both the doctor and the patient was statistically significantly greater in the T + F group at all three follow-ups. At week 7, a good or excellent response was achieved by 96% patients in the T + F group as compared to 62% in the T group ($p = 0.001$).

Figures 1-4 show the daily severities of symptoms as assessed by the patients. Symptoms were consistently worse for patients in the T group and the difference between the groups was greatest between days 20 to 50, (i.e. when the pollen levels rose). There was less worsening of symptoms compared to baseline with regard to all symptoms for the T + F group, although this effect was more pronounced for nasal symptoms.

Similar numbers of side-effects were reported in each treatment group. The most commonly reported reaction in the T + F group was nasal irritation (ten patients), while drowsiness was most frequently reported in the T group (nine patients). Nausea was also reported five times in the latter group. Other side-effects in both groups were those that could be expected with antihistamine therapy. Details of side-effects are given in Table 3.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.